Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

$24.99

Common-Size Income Statement
Quarterly Data

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Pfizer Inc., common-size consolidated income statement (quarterly data)

Microsoft Excel
3 months ended: Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Product revenues
Alliance revenues
Royalty revenues
Revenues (legacy)
Revenues
Cost of sales
Gross profit
Selling, informational and administrative expenses
Research and development expenses
Acquired in-process research and development expenses
Amortization of intangible assets
Restructuring charges and certain acquisition-related costs
Operating income (loss)
Gain on completion of Consumer Healthcare JV transaction
Other income (deductions), net
Income (loss) from continuing operations before (provision) benefit for taxes on income (loss)
(Provision) benefit for taxes on income (loss)
Income (loss) from continuing operations
Discontinued operations, net of tax
Net income (loss) before allocation to noncontrolling interests
Net income attributable to noncontrolling interests
Net income (loss) attributable to Pfizer Inc. common shareholders

Based on: 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).


The financial data reveals several notable trends and fluctuations over the reported periods. Revenue composition shows product revenues ranging mostly in the low to mid 80% range, demonstrating a generally dominant contribution, while alliance and royalty revenues together make up the complementary share with some variability but stable overall presence.

Cost of sales as a percentage of revenues experiences significant volatility, with notable spikes reaching nearly -69% in one period and fluctuating considerably across quarters. Despite these fluctuations, gross profit margins remain positive but variable, reflecting the impact of changing cost structures; margins range broadly from approximately 31% to over 80% across the timeline, indicating periods of compression and expansion in profitability at the gross level.

Operating expenses including selling, informational and administrative costs tend to vary between roughly -10% and -32%, showing periods of cost efficiency and others of increased spending or potentially restructuring activities. Research and development expenses, another major cost component, generally range between approximately -8% and -29%, indicating a sustained but varying investment in current and future product development.

Amortization of intangible assets remains relatively stable as a small but consistent expense, generally between -4% and -9%. Restructuring charges and acquisition-related costs display occasional spikes, such as a sharp increase to nearly -18% in one reporting period, suggestive of significant one-time charges or strategic realignments during certain quarters.

Operating income shows considerable volatility including some negative swings, decreasing notably in a few quarters but generally recovering later on, with percentages fluctuating from nearly -30% to more than 44%. Income from continuing operations before taxes and income taxes themselves follow similar patterns with variability but overall positive contribution in most quarters.

Net income attributable to common shareholders fluctuates widely, with several periods of positive returns exceeding 30%, contrasted by some quarters exhibiting negative outcomes, indicating earnings sensitivity to underlying cost and revenue changes as well as tax and other income variations.

Discontinued operations and net income attributable to noncontrolling interests are relatively minor in proportion and show no consistent directional trend. Overall, the data illustrates that profitability margins and expense management have encountered periods of strain and recovery, reflecting dynamic market conditions and internal operational adjustments over the reported periods.